In contrast to the previously described F1174C/L/V resistance mutations, the F1174S mutation sensitized EML4-ALK V3a/b to crizotinib, the first generation ALK TKI FDA approved for ALK-positive NSCLC. Here, EML4 is linked to non-small cell lung carcinoma.